TRAIL Antikörper
Kurzübersicht für TRAIL Antikörper (ABIN187524)
Target
Alle TRAIL (TNFSF10) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Spezifität
- Recognizes human TRAIL Species Reactivity: Human.
-
Immunogen
- Recombinant human soluble TRAIL (Apo-2L)
-
Isotyp
- IgG2b
-
-
-
-
Applikationshinweise
- Western blotting Flow Cytometry Immunohistochemistry: Frozen sections Immunoprecipitation ELISA The optimal dilution for a specific application should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- 100 µl of purified antibody in PBS containing 0.02% NaN3. Concentration 1 mg/ml IgG.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
-
- TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
-
Andere Bezeichnung
- CD253 / TRAIL
-
Hintergrund
- Tumor necrosis factor (TNF-)-related apoptosis-inducing ligand (TRAIL, APO-2L) is thought to regulate cell death events in the immune system through TRAIL-R1 (DR4) and TRAIL-R2 (DR5), members of the TNF receptor superfamily. Like the death receptors, including Fas and TNF-R, TRAIL-R1 and TRAIL-R2 have death domains in their cytoplasmic tails that recruit proteins to initiate a cell death signaling cascade. TRAIL (APO-2L) is a 34 kDa type II transmembrane protein. TRAIL forms trimers and is a member of the TNF ligand family. Interaction between TRAIL and TRAIL-R1 and/or TRAIL-R2 rapidly induces apoptosis of TRAIL-sensitive cells. TRAIL can be injected into mice without toxic side effects. Many tumor cells are killed by TRAIL and TRAIL is currently being considered as on of the most promising potential new cancer therapeutics.
-
Pathways
- Apoptose, Positive Regulation of Endopeptidase Activity
Target
-